Suppr超能文献

澳大利亚和新西兰急性心力衰竭住院后的长期生存和预期寿命。

Long-term survival and life expectancy following an acute heart failure hospitalization in Australia and New Zealand.

机构信息

Department of Pharmacology, Pondicherry Institute of Medical Sciences, Puducherry, India.

Department of Cardiology, The Prince Charles Hospital, Brisbane, QLD, Australia.

出版信息

Eur J Heart Fail. 2022 Sep;24(9):1519-1528. doi: 10.1002/ejhf.2595. Epub 2022 Aug 2.

Abstract

AIMS

Contemporary long-term survival following a heart failure (HF) hospitalization is uncertain. We evaluated survival up to 10 years after a HF hospitalization using national data from Australia and New Zealand, identified predictors of survival, and estimated the attributable loss in life expectancy.

METHODS AND RESULTS

Patients hospitalized with a primary diagnosis of HF from 2008-2017 were identified and all-cause mortality assessed by linking with Death Registries. Flexible parametric survival models were used to estimate survival, predictors of survival and loss in life expectancy. A total of 283 048 patients with HF were included (mean age 78.2 ± 12.3 years, 50.8% male). Of these, 48.3% (48.1-48.5) were surviving by 3 years, 34.1% (33.9-34.3) by 5 years and 17.1% (16.8-17.4) by 10 years (median survival 2.8 years). Survival declined with age with 53.4% of patients aged 18-54 years and 6.2% aged ≥85 years alive by 10 years (adjusted hazard ratio [aHR] for mortality 4.84, 95% confidence interval [CI] 4.65-5.04 for ≥85 years vs. 18-54 years) and was worse in male patients (aHR 1.14, 95% CI 1.13-1.15). Prior HF (aHR 1.20, 95% CI 1.18-1.22), valvular and rheumatic heart disease (aHR 1.11, 95% CI 1.10-1.13) and vascular disease (aHR 1.07, 95% CI 1.04-1.09) were cardiovascular comorbidities most strongly associated with long-term death. Non-cardiovascular comorbidities and geriatric syndromes were common and associated with higher mortality. Compared with the general population, HF was associated with a loss of 7.3 years in life expectancy (or 56.6% of the expected life expectancy) and reached 20.5 years for those aged 18-54 years.

CONCLUSION

Less than one in five patients hospitalized for HF were surviving by 10 years with patients experiencing almost 60% loss in life expectancy compared with the general population, highlighting the considerable persisting societal burden of HF. Concerted multidisciplinary efforts are needed to improve post-hospitalization outcomes of HF.

摘要

目的

心力衰竭(HF)住院后的当代长期生存情况尚不确定。我们使用来自澳大利亚和新西兰的全国数据评估了 HF 住院后长达 10 年的生存情况,确定了生存的预测因素,并估计了预期寿命的损失。

方法和结果

从 2008 年至 2017 年,确定了因原发性 HF 住院的患者,并通过与死亡登记处的链接评估了全因死亡率。使用灵活的参数生存模型来估计生存情况、生存预测因素和预期寿命损失。共纳入 283048 例 HF 患者(平均年龄 78.2±12.3 岁,50.8%为男性)。其中,3 年内 48.3%(48.1-48.5)存活,5 年内 34.1%(33.9-34.3)存活,10 年内 17.1%(16.8-17.4)存活(中位生存时间为 2.8 年)。随着年龄的增长,生存率下降,18-54 岁的患者中有 53.4%,≥85 岁的患者中有 6.2%在 10 年内存活(≥85 岁与 18-54 岁相比,死亡率的调整后危险比[aHR]为 4.84,95%置信区间[CI]为 4.65-5.04),男性患者的情况更差(aHR 为 1.14,95%CI 为 1.13-1.15)。既往 HF(aHR 为 1.20,95%CI 为 1.18-1.22)、瓣膜性和风湿性心脏病(aHR 为 1.11,95%CI 为 1.10-1.13)和血管疾病(aHR 为 1.07,95%CI 为 1.04-1.09)是与长期死亡最密切相关的心血管合并症。非心血管合并症和老年综合征很常见,并与更高的死亡率相关。与普通人群相比,HF 导致预期寿命损失 7.3 年(或预期寿命的 56.6%),对于 18-54 岁的人群,这一数字达到 20.5 年。

结论

不到五分之一的 HF 住院患者在 10 年内存活,与普通人群相比,这些患者的预期寿命损失近 60%,突出了 HF 持续存在的巨大社会负担。需要多学科协同努力,改善 HF 患者的出院后结局。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1fe6/9804480/a6b0f1de9c3a/EJHF-24-1519-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验